AOSD 보고서 : 인사이트
AOSD 보고서 : 주요 강점
AOSD 보고서 : 평가
미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본의 성인 발병 스틸병(AOSD) 시장을 조사했으며, 질환의 배경과 개요, 역학, 치료 및 관리 개요, 시장 촉진요인 및 장벽, 미충족 수요, 시판 중인 의약품 및 파이프라인 의약품의 프로파일, 주요 국가별 시장 규모 추정 및 예측, 경쟁 상황 등을 정리하여 최적의 기회를 발굴하고 시장 잠재력을 평가합니다.
DelveInsight's "Adult-onset Still's Disease (AOSD) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AOSD, historical and forecasted epidemiology, as well as the AOSD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The AOSD market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM AOSD market size from 2020 to 2034. The report also covers AOSD treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
AOSD overview
AOSD is a rare systemic inflammatory disorder characterized by an unknown etiology, leading to significant morbidity. Clinically, it presents with a constellation of symptoms, including high fever, a distinctive rash, prolonged joint pain, and systemic manifestations such as sore throat, splenomegaly, hepatomegaly, and lymphadenopathy. While the precise causes remain elusive, AOSD may be triggered by environmental factors or infections in genetically predisposed individuals. Risk factors include a history of autoimmune diseases and age, as it typically affects adults in their 20s to 40s. The complexity of diagnosis and variability in symptom presentation contribute to challenges in management and treatment, highlighting the need for greater awareness and research into this condition.
AOSD diagnosis
The diagnosis of AOSD necessitates a comprehensive clinical evaluation, including a detailed patient history and the identification of characteristic clinical findings. As AOSD is primarily a diagnosis of exclusion, it requires ruling out other inflammatory and autoimmune disorders. Diagnostic procedures typically include blood tests that reveal specific hematological changes, such as elevated white blood cell counts and anemia. A critical component is the erythrocyte sedimentation rate (ESR) test, which assesses systemic inflammation. Additional tests may encompass C-reactive protein (CRP) levels, liver function tests, and serological evaluations for other autoimmune diseases. Ultimately, a combination of clinical criteria and laboratory findings guides the diagnosis, emphasizing the need for a systematic approach to effectively identify AOSD.
AOSD treatment
The treatment landscape for AOSD is characterized by limited options that primarily include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and antirheumatic agents. Given the disease's highly variable clinical course-ranging from self-limiting forms to potentially life-threatening complications-no single optimal therapy has been universally established; treatment often requires individualization based on patient response. In cases where NSAIDs and corticosteroids are insufficient, the introduction of biologic disease-modifying antirheumatic drugs (bDMARDs) represents a significant advancement. The recent FDA and European approvals of Anakinra, Canakinumab, and Tocilizumab have notably transformed AOSD management, offering targeted therapies that address the underlying inflammatory processes. These biologics provide clinicians with new avenues for effectively managing the disease, thereby improving patient outcomes and overall quality of life.
As the market is derived using a patient-based model, the AOSD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of AOSD, total diagnosed prevalent cases of AOSD, gender-specific diagnosed prevalent cases of AOSD, and complication associated diagnosed prevalent cases of AOSD in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
Marketed Drugs
ILARIS (canakinumab): NOVARTIS
ILARIS (canakinumab), a human monoclonal anti-human IL-1B antibody of the IgG1/? isotype, was approved by the FDA in June 2020, for the treatment of AOSD in patients aged 2 years and older, including both systemic juvenile idiopathic arthritis (SJIA) and AOSD. Canakinumab works by binding to IL-1B and neutralizing its activity, thus blocking its interaction with IL-1 receptors, a crucial mechanism in controlling the inflammatory response in conditions like AOSD. The FDA granted ILARIS Priority Review designation, recognizing its potential to significantly improve the safety or effectiveness of treating a serious condition.
KINERET (anakinra): Swedish Orphan Biovitrum
KINERET (anakinra) is indicated in Europe for the treatment of rheumatoid arthritis (RA) in adults who have had an inadequate response to methotrexate alone, and for treating cryopyrin-associated periodic syndromes (CAPS) in patients aged 8 months and older with a body weight of 10 kg or more. It is also approved for treating Still's disease, including SJIA and AOSD with moderate to high disease activity or continued disease activity after NSAIDs or glucocorticoids. KINERET can be administered as monotherapy or in combination with other anti-inflammatory drugs and DMARDs. Anakinra received US orphan drug status from the FDA in September 2015.
ACTEMRA (tocilizumab): Genentech (ROCHE)
ACTEMRA (tocilizumab), a humanized anti-human IL-6 receptor monoclonal antibody, is approved for the treatment of AOSD in both the United States and Japan. The FDA granted approval in 2017, recognizing ACTEMRA's efficacy in targeting IL-6 receptors to mitigate the inflammatory response associated with AOSD. In May 2019, Chugai Pharmaceutical announced that it had secured regulatory approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for ACTEMRA Intravenous Infusion (80 mg, 200 mg, and 400 mg) for adult Still's disease, particularly in cases unresponsive to existing therapies, along with an additional dosing regimen. ACTEMRA'S approval underscores its therapeutic significance in addressing unmet needs in this challenging condition.
Emerging Drugs
Tadekinig Alfa: AB2 Bio
Tadekinig alfa is a recombinant Interleukin-18 Binding Protein (r-hIL-18BP) designed to target IL-18, a key inflammatory cytokine involved in various inflammatory diseases. In healthy individuals, naturally occurring IL-18BP maintains low levels of free IL-18, but in patients with certain inflammatory conditions, this balance is disrupted, leading to elevated free IL-18 levels and pathological inflammation. By administering AB2 Bio's exogenous recombinant human IL-18BP, the IL-18/IL-18BP balance is restored, effectively removing excess free IL-18 and reducing inflammation.
Drug Class Insights
The treatment of AOSD involves several classes of medications tailored to address varying degrees of inflammation and disease severity. Nonsteroidal anti-inflammatory drugs (NSAIDs) serve as first-line therapies to alleviate pain and reduce inflammation, though their efficacy may be limited in more severe cases. When NSAIDs prove inadequate, corticosteroids are commonly prescribed to provide rapid anti-inflammatory effects and immune suppression. For patients who do not respond to these conventional therapies, biologic disease-modifying antirheumatic drugs (bDMARDs) are increasingly utilized, targeting specific pathways in the inflammatory process to improve clinical outcomes. Additionally, antirheumatic agents may be employed to help modulate the immune response and control disease activity. The strategic use of these drug classes underscores the importance of individualized treatment plans that address the unique clinical presentation and progression of AOSD in each patient.
AOSD is an autoinflammatory syndrome driven by the innate immune system, characterized by symptoms such as fever, rash, arthritis, pharyngitis, and hepatic and splenic involvement. Due to the rarity of AOSD and a lack of large-scale studies, diagnosis is often challenging, leading to an empirical treatment approach based on small retrospective case series.
The current treatment options include NSAIDs and corticosteroids, which serve as first-line therapies. However, many patients do not achieve remission with NSAIDs, prompting the use of DMARDs and biologics when corticosteroids fail. Biologic agents targeting the inflammatory pathways, such as interleukin (IL) receptor antagonists and TNF inhibitors, have emerged as promising treatments. Notably, KINERET (anakinra), an IL-1 receptor antagonist, is commonly prescribed for refractory AOSD patients, while ILARIS (canakinumab) has also been approved for treating AOSD, establishing a significant therapeutic advance. In Japan, ACTEMRA (tocilizumab), an anti-IL-6 receptor monoclonal antibody, has been approved for AOSD patients who do not respond sufficiently to existing therapies.
Emerging therapies include Tadekinig alfa, a recombinant IL-18 Binding Protein under development by AB2 Bio, which has shown promise in earlier Phase II trials. However, a lack of recent data regarding its efficacy in AOSD limits its inclusion in future forecasts. Overall, the treatment landscape for AOSD continues to evolve, with ongoing research aimed at enhancing therapeutic options for affected individuals.
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020-2034. For example, Tadekinig alfa is expected to enter the US market in 20XX and is projected to have a XX uptake during the forecast period.
AOSD Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.
Pipeline development activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for AOSD.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on AOSD evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; San Joaquin General Hospital * French Camp, USA; Department of Rheumatology, The University of Chicago Medical Center, Chicago, IL, USA, among others, were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or AOSD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Physician's View
As per the KOLs from the US, There are often delays in diagnosis due to the infrequency of the condition and the nonspecific clinical presentation. A definitive diagnostic test has yet to be discovered. Measures of ferritin may only be useful when they are extremely elevated, and clinical suspicion is already high, or as a part of fulfilling diagnostic criteria.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
To analyze the effectiveness of these therapies, have calculated their attributed analysis by giving them scores based on their ability to improve atrial and ventricular dimension/function and ability to regulate heart rate.
Further, the therapies' safety is evaluated wherein the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials, which directly affects the safety of the molecule in the upcoming trials. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
AOSD report insights
AOSD report key strengths
AOSD report assessment
Market Insights
Epidemiology Insights
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies